Paradigm Shift in Prostate Cancer Diagnosis: Pre-Biopsy Prostate Magnetic Resonance Imaging and Targeted Biopsy

Overview

Journal Korean J Radiol

Specialty Radiology

Date 2022 May 13

PMID 35555886

Authors

Jung Jae Park

Chan Kyo Kim

Affiliations

Soon will be listed here.

Abstract

With regard to the indolent clinical characteristics of prostate cancer (PCa), the more selective detection of clinically significant PCa (CSC) has been emphasized in its diagnosis and management. Magnetic resonance imaging (MRI) has advanced technically, and recent international cooperation has provided a standardized imaging and reporting system for prostate MRI. Accordingly, prostate MRI has recently been investigated and utilized as a triage tool before biopsy to guide tissue sampling to increase the detection rate of CSC beyond the staging tool for patients in whom PCa was already confirmed on conventional systematic biopsy. Radiologists must understand the current paradigm shift for better PCa diagnosis and management. This article reviewed the recent literature, demonstrating the diagnostic value of pre-biopsy prostate MRI with targeted biopsy and discussed unsolved issues regarding the paradigm shift in the diagnosis of PCa.

Citing Articles

Deep learning-accelerated T2WI of the prostate for transition zone lesion evaluation and extraprostatic extension assessment.

Kim D, Choi M, Lee Y, Eun Rha S, Nickel M, Lee H Sci Rep. 2024; 14(1):29249.

PMID: 39587164 PMC: 11589747. DOI: 10.1038/s41598-024-79348-5.

Prediction of high-risk prostate cancer based on the habitat features of biparametric magnetic resonance and the omics features of contrast-enhanced ultrasound.

Huang F, Huang Q, Liao X, Gao Y Heliyon. 2024; 10(18):e37955.

PMID: 39323806 PMC: 11423289. DOI: 10.1016/j.heliyon.2024.e37955.

Advanced prostate cancer diagnosed by bone metastasis biopsy immediately after initial negative prostate biopsy: a case report and literature review.

Liu M, Xie Z, Tang W, Liang G, Zhao Z, Wu T Front Oncol. 2024; 14:1365969.

PMID: 38800391 PMC: 11116681. DOI: 10.3389/fonc.2024.1365969.

Use of Imaging and Biopsy in Prostate Cancer Diagnosis: A Survey From the Asian Prostate Imaging Working Group.

Wang L, Jinzaki M, Tan C, Oh Y, Shinmoto H, Lee C Korean J Radiol. 2023; 24(11):1102-1113.

PMID: 37899520 PMC: 10613851. DOI: 10.3348/kjr.2023.0644.

[Prostate Imaging Reporting and Data System (PI-RADS) v 2.1: Overview and Critical Points].

Kim C J Korean Soc Radiol. 2023; 84(1):75-91.

PMID: 36818694 PMC: 9935951. DOI: 10.3348/jksr.2022.0169.

References

Dahnert W, Hamper U, Eggleston J, Walsh P, Sanders R . Prostatic evaluation by transrectal sonography with histopathologic correlation: the echopenic appearance of early carcinoma. Radiology. 1986; 158(1):97-102. DOI: 10.1148/radiology.158.1.3510032. View

Schoots I, Roobol M, Nieboer D, Bangma C, Steyerberg E, Hunink M . Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol. 2014; 68(3):438-50. DOI: 10.1016/j.eururo.2014.11.037. View

Labanaris A, Engelhard K, Zugor V, Nutzel R, Kuhn R . Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. Prostate Cancer Prostatic Dis. 2009; 13(1):65-70. DOI: 10.1038/pcan.2009.41. View

Porpiglia F, Manfredi M, Mele F, Cossu M, Bollito E, Veltri A . Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer. Eur Urol. 2016; 72(2):282-288. DOI: 10.1016/j.eururo.2016.08.041. View

Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M . Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol. 2009; 55(5):1037-63. DOI: 10.1016/j.eururo.2009.01.036. View

Tamada T, Kido A, Takeuchi M, Yamamoto A, Miyaji Y, Kanomata N . Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer. Eur J Radiol. 2019; 121:108704. DOI: 10.1016/j.ejrad.2019.108704. View

Vargas H, Akin O, Shukla-Dave A, Zhang J, Zakian K, Zheng J . Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology. 2012; 265(2):478-87. PMC: 3480819. DOI: 10.1148/radiol.12120041. View

van der Leest M, Cornel E, Israel B, Hendriks R, Padhani A, Hoogenboom M . Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large.... Eur Urol. 2018; 75(4):570-578. DOI: 10.1016/j.eururo.2018.11.023. View

Kwak J, Hong C, Pinto P, Williams M, Xu S, Kruecker J . Is visual registration equivalent to semiautomated registration in prostate biopsy?. Biomed Res Int. 2015; 2015:394742. PMC: 4363498. DOI: 10.1155/2015/394742. View

10.

Corcoran N, Hong M, Casey R, Hurtado-Coll A, Peters J, Harewood L . Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int. 2011; 108(8 Pt 2):E202-10. DOI: 10.1111/j.1464-410X.2011.10119.x. View

11.

Franiel T, Stephan C, Erbersdobler A, Dietz E, Maxeiner A, Hell N . Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning. Radiology. 2011; 259(1):162-72. DOI: 10.1148/radiol.10101251. View

12.

Kattan M, Eastham J, Stapleton A, Wheeler T, Scardino P . A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90(10):766-71. DOI: 10.1093/jnci/90.10.766. View

13.

Tan N, Lin W, Khoshnoodi P, Asvadi N, Yoshida J, Margolis D . In-Bore 3-T MR-guided Transrectal Targeted Prostate Biopsy: Prostate Imaging Reporting and Data System Version 2-based Diagnostic Performance for Detection of Prostate Cancer. Radiology. 2016; 283(1):130-139. PMC: 5375629. DOI: 10.1148/radiol.2016152827. View

14.

Yaxley A, Yaxley J, Thangasamy I, Ballard E, Pokorny M . Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions. BJU Int. 2017; 120 Suppl 3:43-50. DOI: 10.1111/bju.13971. View

15.

Westphalen A, McCulloch C, Anaokar J, Arora S, Barashi N, Barentsz J . Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology. 2020; 296(1):76-84. PMC: 7373346. DOI: 10.1148/radiol.2020190646. View

16.

Matoso A, Epstein J . Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology. 2018; 74(1):135-145. DOI: 10.1111/his.13712. View

17.

Park B, Lee H, Kim C, Choi H, Park J . Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before rebiopsy. Invest Radiol. 2008; 43(11):789-93. DOI: 10.1097/RLI.0b013e318183725e. View

18.

Ahmed H, El-Shater Bosaily A, Brown L, Gabe R, Kaplan R, Parmar M . Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389(10071):815-822. DOI: 10.1016/S0140-6736(16)32401-1. View

19.

Shigemura K, Motoyama S, Yamashita M . Do additional cores from MRI cancer-suspicious lesions to systematic 12-core transrectal prostate biopsy give better cancer detection?. Urol Int. 2012; 88(2):145-9. DOI: 10.1159/000334375. View

20.

Vargas H, Hotker A, Goldman D, Moskowitz C, Gondo T, Matsumoto K . Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. Eur Radiol. 2015; 26(6):1606-12. PMC: 4803633. DOI: 10.1007/s00330-015-4015-6. View